Filing Flows › Caris Life Sciences (CAI) › Guidance history
Caris Life Sciences (CAI) guidance history: what it guided and what it reported
Caris Life Sciences gave guidance in 6 earnings releases on file since Aug 12, 2025. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +12.0% against the guided midpoint. Its releases raised guidance 3 times and lowered it 0 times.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.0B–$1.0B (Feb 26, 2026) → reaffirmed $1.0B–$1.0B (May 7, 2026) → raised $1.0B–$1.0B (Aug 5, 2026) → raised $1.0B–$1.1B (Nov 4, 2026) | — | to be reported | — |
| FY2025 | $675M–$685M (Aug 12, 2025) → raised $720M–$730M (Nov 5, 2025) | $812M | above the range | +12.0% |
GAAP operating expenses
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $590M–$595M (Feb 26, 2026) | — | to be reported | — |
The latest quarter
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Questions
Does Caris Life Sciences beat its guidance?
Caris Life Sciences gave guidance in 6 earnings releases on file since Aug 12, 2025. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +12.0% against the guided midpoint.
How often does Caris Life Sciences raise guidance?
Its earnings releases raised guidance 3 times and lowered it 0 times since Aug 12, 2025.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.